On June 21, Gelunhui reported that Hubei Biocause Pharmaceutical (000627.SZ) stated on the investor interaction platform that China Best Life Insurance maintains a moderate business scale and continues to promote the optimization of business structure, asset allocation structure, and steady promotion of asset-liability matching according to the established development strategy. It continuously strengthens the application of new technologies and talent reserve, improves the company's operational management system, and comprehensively enhances the company's operational capabilities. While ensuring the basic stability of premium income, according to market conditions, it timely adjusts the business rhythm and structure, vigorously promotes the development of long-term value and risk protection-oriented business. At present, the operation of China Best Life Insurance is in order, with accumulated original insurance premium income of about RMB 20.6 billion from January 1, 2024 to May 31, 2024, overall moderate and stable scale.
天茂集团(000627.SZ):目前国华人寿业务经营有序,整体规模适度稳健
Hubei Biocause Pharmaceutical (000627.SZ): Currently, China Best Life Insurance's business operations are orderly, and the overall scale is moderate and stable.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.